Artivion Financial Results
Artivion reported Q3 2026 revenue of $123.8 million, a 9% increase year-over-year, driven by strong performance in On-X and stent grafts. The company narrowed its full-year 2026 revenue guidance to $484-$492 million and is preparing for the U.S. commercial launch of NEXUS in January 2027.
- Term
- Q3 2026
“In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.”
Pat Mackin, Chairman, President, and Chief Executive Officer
“Overall, we are encouraged by our third quarter performance and the progress we have made so far in 2026. With the recent PMAs of AMDS and NEXUS in the U.S., and ARCEVO LSA on track with enrollment in the ARTIZEN IDE trial, we believe we are on track to being the only company with a comprehensive aortic arch portfolio, which represents an approximately $330 million annual U.S. market opportunity.”
Pat Mackin, Chairman, President, and Chief Executive Officer